New developments in anti-malarial target candidate and product profiles
JN Burrows, S Duparc, WE Gutteridge… - Malaria journal, 2017 - Springer
A decade of discovery and development of new anti-malarial medicines has led to a
renewed focus on malaria elimination and eradication. Changes in the way new anti …
renewed focus on malaria elimination and eradication. Changes in the way new anti …
Experimental infection of human volunteers
M Roestenberg, MA Hoogerwerf… - The Lancet Infectious …, 2018 - thelancet.com
Controlled human infection (CHI) trials, in which healthy volunteers are experimentally
infected, can accelerate the development of novel drugs and vaccines for infectious …
infected, can accelerate the development of novel drugs and vaccines for infectious …
Controlled human malaria infection: applications, advances, and challenges
Controlled human malaria infection (CHMI) entails deliberate infection with malaria
parasites either by mosquito bite or by direct injection of sporozoites or parasitized …
parasites either by mosquito bite or by direct injection of sporozoites or parasitized …
Safety, tolerability, pharmacokinetics, and activity of the novel long-acting antimalarial DSM265: a two-part first-in-human phase 1a/1b randomised study
JS McCarthy, J Lotharius, T Rückle… - The Lancet Infectious …, 2017 - thelancet.com
Background DSM265 is a novel antimalarial that inhibits plasmodial dihydroorotate
dehydrogenase, an enzyme essential for pyrimidine biosynthesis. We investigated the …
dehydrogenase, an enzyme essential for pyrimidine biosynthesis. We investigated the …
A controlled human malaria infection model enabling evaluation of transmission-blocking interventions
KA Collins, CYT Wang, M Adams, H Mitchell… - The Journal of clinical …, 2018 - jci.org
BACKGROUND. Drugs and vaccines that can interrupt the transmission of Plasmodium
falciparum will be important for malaria control and elimination. However, models for early …
falciparum will be important for malaria control and elimination. However, models for early …
A Phase II pilot trial to evaluate safety and efficacy of ferroquine against early Plasmodium falciparum in an induced blood-stage malaria infection study
JS McCarthy, T Rückle, E Djeriou, C Cantalloube… - Malaria journal, 2016 - Springer
Background Ferroquine (SSR97193) is a candidate anti-malarial currently undergoing
clinical trials for malaria. To better understand its pharmacokinetic (PK) and …
clinical trials for malaria. To better understand its pharmacokinetic (PK) and …
[HTML][HTML] The early preclinical and clinical development of cipargamin (KAE609), a novel antimalarial compound
SAM Bouwman, R Zoleko-Manego, KC Renner… - Travel Medicine and …, 2020 - Elsevier
Background Cipargamin (KAE609) is a novel spiroindolone class drug for the treatment of
malaria, currently undergoing phase 2 clinical development. This review provides an …
malaria, currently undergoing phase 2 clinical development. This review provides an …
High prevalence of Plasmodium falciparum gametocyte infections in school-age children using molecular detection: patterns and predictors of risk from a cross …
JE Coalson, JA Walldorf, LM Cohee, MD Ismail… - Malaria journal, 2016 - Springer
Background In endemic areas, many people experience asymptomatic Plasmodium
infections, particularly older children and adults, but their transmission contribution is …
infections, particularly older children and adults, but their transmission contribution is …
A phase 1, placebo-controlled, randomized, single ascending dose study and a volunteer infection study to characterize the safety, pharmacokinetics, and antimalarial …
JS McCarthy, C Donini, S Chalon… - Clinical Infectious …, 2020 - academic.oup.com
Background MMV390048 is the first Plasmodium phosphatidylinositol 4-kinase inhibitor to
reach clinical development as a new antimalarial. We aimed to characterize the safety …
reach clinical development as a new antimalarial. We aimed to characterize the safety …
Defining the next generation of severe malaria treatment: a target product profile
J Achan, A Barry, D Leroy, G Kamara, S Duparc… - Malaria Journal, 2024 - Springer
Background Severe malaria is a life-threatening infection, particularly affecting children
under the age of 5 years in Africa. Current treatment with parenteral artemisinin derivatives …
under the age of 5 years in Africa. Current treatment with parenteral artemisinin derivatives …